SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : CYPB - Cypress BioScience
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: arnold silver who wrote ()3/9/2000 2:51:00 PM
From: T A P  Read Replies (1) of 586
 
CYPB UPDATE!!
Todays CYPB news is a very good step for increasing distribution to reach its goals in cornering the $200 million estimated market for Prosorba Column of which CYPB & partner Fresenius HemoCare with more than 2,000 employees worldwide who are actively engaged in extending its global reach from its leading European market platform are well postioned to do.
T A P really likes the long term prospects for CYPB and looks forward to the expected National Insurance approval for Prosorba for RA expected sometime between now and May 22nd. Not only is CYPB a bio-tech with an actively marketed product & revenues, unlike many bio's just in R&D phase, when Phase 2 trials for Cyplex(TM) start back up CYPB should really gain additional exposure.Cyplex really has some very good prospects if and when FDA approved.

T A P has taken a position in CYPB on the open market and is not compensated in any way by any company mentioned! All information can not be guaranteed but is believed accurate and is for purpose of research and is not a solicitation to buy any security and doing so will be done at your own risk. For more information on CYPB see other posts on T A P Internet/Biotech message boards. To join T A P free go to T A P profile for url.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News